Seres Therapeutics Inc (MCRB.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|60||2014||Chairman of the Board, President, Chief Executive Officer|
|41||2014||Chief Financial Officer, Executive Vice President|
|56||2012||Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing|
|59||2012||Chief Scientific Officer, Executive Vice President - Research & Development|
|62||2016||Chief Legal Officer, Executive Vice President and Secretary|
- BRIEF-Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis
- Biotech firms race to recruit good bugs in war on cancer
- BRIEF-Seres Therapeutics Q3 net loss per share $0.17
- BRIEF-Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis
- Drugmakers tackle 'ick' factor with fecal transplant therapies